CA
NZ
UK
AU
IND
US
• Can-Fite BioPharma Ltd. (NYSE: CANF) reported that its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma met its primary safety endpoint and showed durable overall survival.
• What They Are: Pre-funded warrants let investors pay for shares upfront and exercise later at a nominal price, near zero.
• $125 Million in Gross Proceeds: Neurogene (NASDAQ: NGNE) expects roughly $125 million in gross proceeds before fees and any over-allotment exercise.
• $600 Million Offering Size: Abivax (NASDAQ: ABVX) initiated a registered public offering of ADSs totaling roughly $600 million, or about €527 million.
• Up to $8.8 Million Deal: Cadrenal Therapeutics (NASDAQ: CVKD) signed a private placement of up to $8.8 million with a single healthcare-focused institutional investor.
• NYSE American Deficiency Notice: Matinas BioPharma (NYSE American: MTNB) received a June 24, 2026 notice of a continued-listing deficiency.
• All Proposals Adopted: NewcelX (NASDAQ: PUBT) shareholders voted to adopt the full suite of proposals submitted by the board.
• Two Forces at Play: Biotech sessions often pit clinical progress against capital raises, and both moved together in the latest tape.
• Muscle Loss Concern: Rapid weight loss from GLP-1 drugs can strip muscle alongside fat, creating a recognized clinical problem.
• Primary Safety Endpoint Met: Can-Fite BioPharma (NYSE: CANF) said its Phase 2a study of Namodenoson in advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint.
Please wait processing your request...